enhanced neonatal fc receptor function improves protection primate shiv infection 
protect human immunodeficiency virus hiv- infection broadly neutralizing antibodies bnabs must active portals viral entry gastrointestinal cervicovaginal tracts localization persistence antibodies sites influenced neonatal fc receptor fcrn12 whose role protecting infection vivo defined show bnab enhanced fcrn binding increased gut mucosal tissue localization improves protection lentiviral infection non-human primates bnab directed cd4-binding site hiv- envelope env protein denoted vrc013 modified site-directed mutagenesis increase binding affinity fcrn enhanced fcrn-binding mutant bnab denoted vrc01-ls displayed increased transcytosis across human fcrn-expressing cellular monolayers vitro retaining fc gamma riiia binding function including antibody-dependent cell-mediated cytotoxicity adcc activity levels similar vrc01 wild type vrc01-ls threefold longer serum half-life vrc01 non-human primates persisted rectal mucosa even longer detectable serum notably vrc01-lsmediated protection superior afforded vrc01 intrarectal infection simian-human immunodeficiency virus shiv findings suggest modification fcrn binding provides mechanism increase serum half-life also enhance mucosal localization confers immune protection mutations enhance fcrn function therefore increase potency durability passive immunization strategies prevent hiv- infection 
